Expression of p16 in endometrial Cracinoma- hospital based crosssectional Study

Abstract

BACKGROUND: Endometrial carcinoma is 4th most common cancer in females. Endometrial neoplasia incorporates a variety of lesions ranging from benign endometrial hyperplasia to endometrial carcinomas, collectively posing a substantial burden on global public health. P16 is the second most common tumor suppressor gene. Increased expression of p16 was observed in HPV-associated tumors, various high-grade carcinomas and lesions that affect female reproductive system including serous carcinomas of ovaries and endometrium. Squamous cell carcinoma of the uterine cervix, adenocarcinoma of the endocervix, and high-grade squamous intraepithelial lesions found in the vulva, vagina, and anogenital areas. Owing to tumor heterogenicity, a comprehensive understanding of the clinicopathological correlation of p16 expression in endometrial carcinoma is essential to unravel its true diagnostic and prognostic potential. OBJECTIVES The study is aimed to evaluate expression of P16 in endometrial carcinoma, to correlate p16 positivity scores with clinicopathological parameters and to compare p16 expression in endometrial carcinoma and hyperplasia